Literature DB >> 15197303

Chemical production of bispecific antibodies.

Robert F Graziano1, Paul Guptill.   

Abstract

This chapter discusses two related methods for creating Fab' x Fab' chemically linked BsAb. Both methods require the generation of purified F(ab')2 fragments of each antibody and use reagents that react with the free thiols generated upon reduction of interheavy chain disulfide bonds of the F(ab')2 fragments. Upon reduction, the resulting Fabs are then recombined to form a Fab' x Fab' BsAb. 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB) acts to regenerate disulfide bonds between the two Fabs, whereas o-phenylenedimaleimide (o-PDM) acts to form a thioether bond between the two Fabs. After coupling, the bispecific antibody is purified from the uncoupled Fabs by size-exclusion chromatography. The advantages and disadvantages of each conjugation method are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197303     DOI: 10.1385/1-59259-813-7:071

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.

Authors:  Chan Hyuk Kim; Jun Y Axup; Anna Dubrovska; Stephanie A Kazane; Benjamin A Hutchins; Erik D Wold; Vaughn V Smider; Peter G Schultz
Journal:  J Am Chem Soc       Date:  2012-06-06       Impact factor: 15.419

3.  A modular IgG-scFv bispecific antibody topology.

Authors:  Kelly Davis Orcutt; Margaret E Ackerman; Maryelise Cieslewicz; Emmanuel Quiroz; Adrian L Slusarczyk; John V Frangioni; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2009-12-17       Impact factor: 1.650

4.  Bispecific small molecule-antibody conjugate targeting prostate cancer.

Authors:  Chan Hyuk Kim; Jun Y Axup; Brian R Lawson; Hwayoung Yun; Virginie Tardif; Sei Hyun Choi; Quan Zhou; Anna Dubrovska; Sandra L Biroc; Robin Marsden; Jason Pinstaff; Vaughn V Smider; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

Review 5.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

6.  Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity.

Authors:  Li Wei; Fan Dongmei; Yang Ming; Shi Ruizan; Yan Yan; Jiang Linlin; Yan Cihui; Li Shuangjing; Wang Min; Wang Jianxiang; Xiong Dongsheng
Journal:  Cell Oncol (Dordr)       Date:  2012-10-09       Impact factor: 6.730

Review 7.  Protein conjugation with genetically encoded unnatural amino acids.

Authors:  Chan Hyuk Kim; Jun Y Axup; Peter G Schultz
Journal:  Curr Opin Chem Biol       Date:  2013-05-09       Impact factor: 8.822

8.  A novel redox method for rapid production of functional bi-specific antibodies for use in early pilot studies.

Authors:  Jennifer Carlring; Evy De Leenheer; Andrew William Heath
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

9.  Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.

Authors:  Yiren Xu; John Lee; Cuong Tran; Tyler H Heibeck; Willie D Wang; Junhao Yang; Ryan L Stafford; Alexander R Steiner; Aaron K Sato; Trevor J Hallam; Gang Yin
Journal:  MAbs       Date:  2015       Impact factor: 5.857

10.  A detergent-based procedure for the preparation of IgG-like bispecific antibodies in high yield.

Authors:  Jyoti Gupta; Mehboob Hoque; Masihuz Zaman; Rizwan Hasan Khan; M Saleemuddin
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.